Pharmacological consequences of inhaled drug delivery to small airways in the treatment of asthma

Advances in Therapy

Volumn 31, Issue 8, 2014, Pages 803-816

  Bodzenta Łukaszyk, Anna ^a   Kokot, Marek ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Takeda Polska   (Poland)

Author keywords

Asthma; Bronchodilators; Inhaled corticosteroids; Pharmacology of aerosols; Pulmonary deposition; Small airways; Systemic bioavailability of inhaled drugs

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; HYDROCORTISONE; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT;

AEROSOL; AIRWAY; ASTHMA; CARDIOTOXICITY; CORTICOSTEROID THERAPY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; METERED DOSE INHALER; PARTICLE SIZE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 84961289299     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0143-7     Document Type: Review

References (74)

1. Farah CS, King GG, Brown NJ, et al. The role of the small airways in the clinical expression of asthma in adults. J Allergy Clin Immunol. 2012;129:381–7
2. van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol. 2013;131:646–57
3. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(Suppl 2):447–60
4. Morrison JF, Pearson SB. The parasympathetic nervous system and the diurnal variation of lung mechanics in asthma. Respir Med. 1991;85:285–9
5. Hamid Q. Pathogenesis of small airways in asthma. Respiration. 2012;84:4–11
6. Downie SR, Salome Ch M, Verbanck S, Thompson B, Berend N, King GG. Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation. Thorax. 2007;62:684–9
7. Wiggs BR, Hrousis CA, Drazen JM, Kamm RD. On the mechanism of mucosal folding in normal and asthmatic airways. J Appl Physiol. 1997;83:1814–21
8. Grainge CL, Lau LC, Ward JA, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med. 2011;364:2006–15
9. Venegas JG, Winkler T, Musch G, et al. Selforganized patchiness in asthma as a prelude to catastrophic shifts. Nature. 2005;434:777–82
10. Gonem S, Natarajan S, Hartley R, et al. Cluster analysis reveals a distinct small airway- predominant phenotype of asthma. Thorax. 2012;67:A7
11. Weibel ER. Morphometry of the human lung. New York: Academic; 1963
12. Fal AM, Ni_zankowska-Mogilnicka E, S´ liwin´ ski P, Emeryk A, Antczak A, Kruszewski J. Drobne drogi oddechowe w chorobach obturacyjnych płuc. Pneumol Alergol Pol. 2012;80:146–51
13. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1:315–20
14. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFAbeclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346–53
15. Borgstrom L. Deposition patterns with Turbuhaler. J Aerosol Med. 1994;7(Suppl 1):S49–53
16. Tarsin WY, Pearson SB, Assi KH, Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm. 2006;316: 131–7
17. Delvadia R, Hindle M, Longest PW, Byron PR. In vitro tests for aerosol deposition II: IVIVCs for different powder inhalers in normal adults. J Aero Med Pulm Drug Deliv. 2012;26:138–44
18. Tamura G, Sakae H, Fujino S. In vitro evaluation of dry powder inhaler devices of corticosteroid preparations. Allerg Int. 2012;61:149–54
19. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61:518–26
20. Taki M, Marriott C, Zeng XM, Martin GP. Aerodynamic deposition of combination of dry power inhaler in vitro: a comparison of three impactors. Int J Pharm. 2010;388:40–51
21. The Electronic Medicines Compendium (eMC). http://www.medicines.org.uk/emc/. Accessed July 28, 2014
22. Newman SP, Pitcairn GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J. 2000;16:178–83
23. Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med. 2001;95:720–7
24. De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/Formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137–48
25. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006;100:375–84
26. Nave R, Mueller H. From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled drugs. Int J Gen Med. 2013;6:99–107
27. Dalby NR, Eicher J, Zierenberg B. Development of Respimat Soft Mist Inhaler and its utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–55
28. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377:1032–45
29. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104:1215–22
30. Harrison LI, Soria I, Cline AC, Ekholm BP. Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J Pharm Pharmacol. 1999;51:1235–40
31. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377–83
32. Thompson PJ, Davies RJ, Young WF, Grossman AB, Donnell D. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med. 1998;92(Suppl A):33–9
33. Lipworth BJ. The comparative safety/efficacy ratio of HFA-BDP. Respir Med. 2000;94(Suppl D):S21–6
34. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med. 1997;91(Suppl A):22–8
35. Derendorf H, Hochhaus G, Meibohm B, Möllmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S440–6
36. Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticoids. Immunol Allergy Clin North Am. 2005;25:469–88
37. Webner B, Hochhaus G. A pharmacokinetic simulation tool for inhaled corticosteroids. AAPS J. 2013;15:159–71
38. Freiwald M, Valotis A, Kirschbaum A, et al. Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respir Res. 2005;6:21
39. Dekhuijzen PN, Honour JW. Inhaled corticosteroids and the hypothalamic-pituitary-adrenal (HPA) axis: do we understand their interaction? Respir Med. 2000;94:627–31
40. Mulrennan SA, Hogg JS, Teoh RC, Morice AH. Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate. Br J Clin Pharmacol. 2006;63:288–91
41. Fowler SJ, Orr LC, Wilson AM, Sims EJ, Lipworth BJ. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. J Clin Pharmacol. 2001;52:93–5
42. Agertoft L, Laulund LW, Harrison LI, Pedersen S. Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol. 2003;35:192–9
43. GINA—Global initiative for asthma. http://www. ginasthma.org/. Accessed July 28, 2014
44. Van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone dipropionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults. Int J Clin Pract. 2004;58:678–88
45. Van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone dipropionate extrafine aerosol) in asthma (part 2): an update of clinical experience in children. Int J Clin Pract. 2004;58:786–94
46. Currie GP, Fowler SJ, Wilson AM, Sims EJ, Orr LC, Lipworth BJ. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thorax. 2002;57:865–8
47. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol. 2003;43:365–78
48. Rohatagi S, Appajosyula S, Derendorf H, et al. Riskbenefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol. 2004;44:37–47
49. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther. 2005;12:201–9
50. Xu J, Nave R, Lahu G, Derom E, Derendorf H. Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. J Ciln Pharmacol. 2010;50:1118–27
51. Winkler J, Hochaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1:356–63
52. Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest. 2005;128:1104–14
53. Bateman ED. Efficacy and safety of high-dose ciclesonide for the treatment of severe asthma. Expert Rev Respir Med. 2013;7:339–48
54. Gentile DA, Skoner DP. New asthma drugs: small molecule inhaled corticosteroids. Curr Opin Pharmacol. 2010;10:260–5
55. van den Berge M, ten Hacken NH, van der Wiel E, Postma DS. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy. 2013;68:16–26
56. Howarth PH. Why particle size should affect clinical response to inhaled therapy. J Aerosol Med. 2001;14(Suppl 1):S27–34
57. Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996;51:977–80
58. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of b2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–504
59. Warnier MJ, Rutten FH, Kors JA, et al. Cardiac arrhythmias in adult patients with asthma. J Asthma. 2012;49:942–6
60. Desantiago J, Ai X, Islam M, et al. Arrhythmogenic effects of beta2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ Res. 2008;102:1389–97
61. Singh S, Loke YK, Enright P, Furberg CD. Proarrhythmic and pro-ischemic effects of inhaled anticholinergic medications. Thorax. 2013;68:114–6
62. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomized controlled trials. BMJ. 2011;342:d3215
63. Mathioudakis AG, Mathioudakis GA. Tiotropium inhaler devices: seeking convenience when mortality is at stake? J Aerosol Med Pulm Drug Deliv. 2013;26:120
64. Wise RA, Anzueto A, Cotton D, et al. Tiotropium respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369:1491–501
65. Salpeter SR, Wall AJ, Buckley NS. Long-acting Betaagonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med. 2010;123:322–8
66. Breekveldt-Postma NS, Koerselman J, Erkens JA, et al. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf. 2008;17:411–22
67. Perrin K, Williams M, Wijesinghe M, James K, Weatherall M, Beasley R. Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting b-agonist inhaler therapy in asthma. J Allergy Clin Immunol. 2010;126:505–10
68. Paggiaro P, Nicolini G, Papi A. Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma. Expert Rev Resp Med. 2008;292:161–6
69. Häussermann S, Acerbi D, Brand P, et al. Lung deposition of formoterol HFA (Atimos)
70. Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J. 1993;6:204–10
71. O’Connor BJ, Kilfeather S, Cheung D, et al. Efficacy and safety of ciclesonide in patients with severe asthma: a 12-week, double-blind, randomized, parallel-group study with long-term (1-year) follow-up. Expert Opin Pharmacother. 2010;11:2791–803
72. Cohen J, Postma DS, Douma WR, Vonk JM, De Boer AH, ten Hacken NH. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J. 2011;37:532–40
73. Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int. 2010;59:59–66
74. Derom E, Louis R, Tiesler C, Engelstätter R, Kaufman JM, Joos GF. Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J. 2009;33:1277–86.